Clinical Trial Update: Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating personalized, model-informed induction dosing of infliximab in Crohn's disease has been terminated with results posted in March 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Crohn Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2026-03-11